美国Emergent BioSolutions
Emergent BioSolutions公司是一家生物制药企业，致力于免疫相关生物产品的开发、生产和商业化，其产品包括疫苗和疗法，能帮助人体免疫系统预防或治疗疾病。Emergent的上市产品BioThrax® （炭疽吸附疫苗）是美国食品药品管理局（FDA）唯一认可的预防炭疽感染的疫苗。Emergent公司准备启动和已经启动的开发项目中还有侧重于炭疽、肉毒中毒、伤寒、结核、乙肝和衣原体的一些计划。

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission —to protect life. We develop, manufacture and commercialize immune related biologics, vaccines and biotherapeutics that assist the body’s immune system to prevent or treat infectious and other life threatening diseases. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our product pipeline also includes: two “next generation” anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine.